Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Smoking 1Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Neurologic Manifestations 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Hyperlipoproteinemia Type II 1Hematologic Neoplasms 1Diabetes Mellitus 1Dementia 1Colorectal Neoplasms 1Colitis, Ulcerative 1Cardiovascular Diseases 1Carcinoma, Hepatocellular 1COVID-19 1

Interventions

Bevacizumab 30pembrolizumab 29Oxaliplatin 28Leucovorin 25Fluorouracil 24Irinotecan 22Cetuximab 22Capecitabine 19Nivolumab 15Specimen Handling 12atezolizumab 11Panitumumab 11Colonoscopy 9Carboplatin 9regorafenib 8Biopsy 8trifluridine tipiracil drug combination 7Trifluridine 7Paclitaxel 7Aspirin 7balstilimab 6Standard of Care 6Cisplatin 6tislelizumab 5encorafenib 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunoglobulin G 5Folfox protocol 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colorectal Neoplasms × Atorvastatin × Clear all
NCT04767984 2026-01-21

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Northwestern University

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Colitis, Ulcerative, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡